MyoKardia Inc v. Annora Pharma Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: MyoKardia, Inc. (Delaware) and Bristol-Myers Squibb Company (Delaware)
  • Defendant: Annora Pharma Private Limited (India) and Hetero USA, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: MyoKardia, Inc. v. Annora Pharma Private Limited, 1:26-cv-00852, D. Del., 07/14/2026
• Venue Allegations: Venue is alleged to be proper for Annora Pharma, an Indian corporation, because it is subject to personal jurisdiction in Delaware. Venue is proper for Hetero USA because it is a Delaware corporation.
• Core Dispute: Plaintiffs allege that Defendants' Abbreviated New Drug Application (ANDA) to market a generic version of the cardiac drug Camzyos® (mavacamten) constitutes an act of infringement of two U.S. patents covering the compound and its method of use.
• Technical Context: The technology involves mavacamten, a small-molecule cardiac myosin inhibitor used for treating obstructive hypertrophic cardiomyopathy (HCM), a genetic heart muscle disease.
• Key Procedural History: This action arises under the Hatch-Waxman Act following Defendants' submission of ANDA No. 221461 to the U.S. Food and Drug Administration (FDA). As part of the ANDA, Defendants filed a Paragraph IV certification, asserting that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by the proposed generic product. Plaintiffs filed this complaint within the 45-day statutory window, triggering an automatic 30-month stay of FDA approval for the ANDA.

Case Timeline

Date	Event
2013-06-21	Earliest Priority Date for RE'050 and '883 Patents
2017-03-07	U.S. Patent No. 9,585,883 Issues
2024-07-23	U.S. Reissue Patent No. 50,050 Issues
2026-06-08	Annora's Paragraph IV Notice Letter Date
2026-07-14	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissue Patent No. 50,050 - "Pyrimidinedione Compounds"

• Patent Identification: U.S. Reissue Patent No. 50,050 ("Pyrimidinedione Compounds"), issued July 23, 2024.

The Invention Explained

• Problem Addressed: The patent's background describes that medical therapies for hypertrophic cardiomyopathy (HCM) are limited to treating symptoms and do not address the underlying cause of the disease, which involves disruptions in the function of the sarcomere, the heart's contractile unit RE'050 Patent, col. 2:4-10
• The Patented Solution: The invention provides novel pyrimidine dione compounds, including mavacamten, and their pharmaceutically acceptable salts RE'050 Patent, abstract These compounds are designed to reduce excessive heart muscle contractility by stabilizing a specific conformation of beta cardiac myosin, thereby decreasing the number of myosin molecules available to participate in the "powerstroke" of muscle contraction and improving cardiac relaxation RE'050 Patent, col. 3:24-44
• Technical Importance: This technology represents a therapeutic approach that targets the fundamental biomechanical cause of HCM, offering a potential alternative to therapies that only manage symptoms RE'050 Patent, col. 2:18-24

Key Claims at a Glance

• The complaint asserts infringement of at least claim 20 of the RE'050 patent Compl. ¶31 Compl. ¶35 Compl. ¶39
• The complaint states that the RE'050 patent claims recite "a series of specifically defined compounds, including mavacamten" Compl. ¶30
• The complaint does not provide the text of the asserted claim or its parent independent claim.

U.S. Patent No. 9,585,883 - "Pyrimidinedione Compounds"

• Patent Identification: U.S. Patent No. 9,585,883 ("Pyrimidinedione Compounds"), issued March 7, 2017.

The Invention Explained

• Problem Addressed: Similar to the RE'050 patent, the '883 patent addresses the lack of medical therapies for HCM that treat the fundamental cause of the disease rather than merely alleviating symptoms ʼ883 Patent, col. 2:4-10
• The Patented Solution: The invention provides a method for treating HCM by administering an effective amount of specific pyrimidine dione compounds, such as mavacamten, to a subject in need thereof ʼ883 Patent, abstract ʼ883 Patent, col. 9:50-52 The compounds work by reducing hypercontractility in the heart muscle, thereby improving cardiac elasticity and relaxation ʼ883 Patent, col. 3:24-44
• Technical Importance: The patent claims a specific therapeutic use for the novel compounds, providing a targeted method for treating HCM by modulating sarcomere function '883 Patent, col. 2:18-24

Key Claims at a Glance

• The complaint asserts infringement of at least claim 18 of the '883 patent Compl. ¶51 Compl. ¶55 Compl. ¶56
• The complaint describes the patent as claiming "a method of treating hypertrophic cardiomyopathy (HCM), comprising administering to a subject in need thereof an effective amount of at least one of a series of compounds, including mavacamten" Compl. ¶50
• The complaint does not provide the text of the asserted claim or its parent independent claim.

III. The Accused Instrumentality

Product Identification

• Defendants' proposed generic mavacamten capsules, submitted for FDA approval under ANDA No. 221461 ("Annora's ANDA Product") Compl. ¶3 The ANDA covers 2.5 mg, 5 mg, 10 mg, and 15 mg dosage strengths Compl. ¶3

Functionality and Market Context

• The accused product is a generic version of Plaintiffs' Camzyos®, which contains the active ingredient mavacamten Compl. ¶26
• Mavacamten is a cardiac myosin inhibitor used to treat adults with obstructive hypertrophic cardiomyopathy Compl. ¶25 The ANDA product is intended to be a bioequivalent and therapeutically equivalent version of the branded drug, for use as described in its proposed labeling Compl. ¶56

IV. Analysis of Infringement Allegations

The complaint does not provide sufficient detail for a claim chart analysis. It is a statutory complaint filed under 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA for a drug claimed in a patent as an act of infringement.

• RE'050 Patent Infringement Allegations: The infringement theory for the RE'050 patent, which contains compound claims, is based on the composition of the accused product itself. The complaint alleges that "Annora's ANDA Product is covered by at least claim 20 of the RE'050 patent" Compl. ¶35 The filing of the ANDA to obtain approval for this allegedly covered product before patent expiration constitutes the act of infringement Compl. ¶37
• '883 Patent Infringement Allegations: The infringement theory for the '883 patent, which contains method-of-use claims, is based on the intended use of the accused product. The complaint alleges that "The use of Annora's ANDA Product in accordance with and as directed by Annora's proposed labeling for Annora's ANDA Product would infringe at least claim 18 of the '883 patent" Compl. ¶56 This suggests a theory of induced infringement, where Defendants' product label would instruct users to perform the patented method of treatment.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

The complaint provides insufficient detail to identify specific claim terms that are likely to be in dispute for the RE'050 patent's compound claims. For the '883 patent's method claims, the following term may be central to the dispute.

• The Term: "treating hypertrophic cardiomyopathy (HCM)"
• Context and Importance: In an ANDA case involving a method-of-use patent, the scope of the "treating" limitation is often critical. The infringement analysis will hinge on whether the indications for use described in the defendant's proposed drug label fall within the scope of "treating HCM" as defined by the patent. Practitioners may focus on this term to determine if there is a legally sufficient basis for induced infringement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification states that ""treat," "treating" and "treatment" refer to any indicia of success in the treatment or amelioration of a pathology," including subjective parameters or simply making the condition "more tolerable to the patient" ʼ883 Patent, col. 6:49-59 This language could support a broad definition encompassing any palliative or symptomatic relief.
  • Evidence for a Narrower Interpretation: The background section distinguishes the invention from prior art therapies that are "limited to the treatment of symptoms and do[] not address the fundamental, underlying cause of disease" ʼ883 Patent, col. 2:5-8 This suggests the patented "treatment" may require addressing the root cause-sarcomere dysfunction-rather than just symptoms, potentially supporting a narrower construction.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for both patents-in-suit Compl. ¶¶41, 62 For the '883 patent, inducement is specifically based on the allegation that Defendants' proposed product labeling will direct and encourage medical professionals and patients to use the generic drug in a manner that infringes the claimed method Compl. ¶56 Compl. ¶60 Contributory infringement is based on the allegation that the accused ANDA product is "not suitable for substantial non-infringing use" Compl. ¶36 Compl. ¶57
• Willful Infringement: The complaint does not explicitly plead "willful infringement" or seek enhanced damages under 35 U.S.C. § 284. However, it does allege that Defendants have knowledge of the patents-in-suit via the Paragraph IV notice letter and have "continued to assert its intent to manufacture, offer for sale, sell, distribute, and/or import Annora's ANDA Product" despite this knowledge Compl. ¶40 Compl. ¶61 It also requests a declaration that the case is "exceptional" for the purpose of awarding attorneys' fees under 35 U.S.C. § 285 Compl., Prayer for Relief ¶ i

VII. Analyst's Conclusion: Key Questions for the Case

• A primary question will be one of patent validity: As is typical in Hatch-Waxman litigation, the case will likely center on Defendants' challenge to the validity of the RE'050 and '883 patents, as asserted in their Paragraph IV certification letter Compl. ¶33 Compl. ¶53 The court will need to determine whether Defendants can prove, by clear and convincing evidence, that the asserted claims are invalid, likely on grounds such as obviousness or lack of adequate written description.
• A second core issue will be one of induced infringement: For the method-of-use '883 patent, a key question will be whether the language in Defendants' proposed product label is sufficient to prove specific intent to encourage or instruct physicians and patients to perform the steps of the patented method, thereby establishing liability for induced infringement under 35 U.S.C. § 271(b).
• Finally, a definitional question may arise regarding the scope of treatment: The interpretation of "treating hypertrophic cardiomyopathy" in the '883 patent claims could be a focal point. The court may need to decide whether the term is limited to addressing the underlying mechanics of the disease, as suggested by the patent's specification, or if it broadly covers any form of symptomatic relief that would be described in the accused product's label.